Globe Life Inc. (GL) · Oct 21, 2026 · Earnings

Globe Life earnings miss as 2026 guidance is cut

Miss — Operating EPS $4.84 vs ~$4.87–$4.91 consensus

Globe Life’s Q3 earnings narrowly missed expectations, while higher claims and Medicare costs forced a 2026 guidance cut despite solid premium growth.

Globe Life is a mature middle-income life and supplemental-health insurer trying to expand its health platform through United American and Evry while maintaining agent-led life growth. Its standing story was still one of durable premium expansion and capital returns, but this quarter exposes execution problems inside the newer health operations.

The quarter was slightly below the earnings bar. Net operating income was $4.84 per diluted share versus $4.81 a year earlier, but published Q3 estimates clustered around roughly $4.87–$4.91, making this a narrow miss rather than an upside surprise.

MetricQ3 2026Q3 2025 / prior referenceRead
Net operating income per diluted share$4.84$4.81Up 1% (Operating Summary)
Net income per diluted share$4.62$4.73Down 2% (Operating Summary)
Total premium revenue$1.311B$1.231BUp 7% (Revenue)
Insurance underwriting income$481.8M$503.1MDown 4% (Insurance Underwriting Income)
Health underwriting margin$115.6M$108.4MUp 7% (Health Underwriting Margin)
Life underwriting margin$458.2M$481.6MDown 5% (Life Underwriting Margin)
Full-year 2026 earnings guidance$15.35–$15.65$15.55–$15.95 previouslyCut (Guidance)
2026 share-repurchase outlook$725M–$775M$670M–$700M previouslyRaised (Capital Return)

The important change is the guidance cut, not the small quarterly miss. Globe Life reduced its full-year 2026 operating-earnings range from $15.55–$15.95 to $15.35–$15.65, blaming high-severity claims at Evry and excess Medicare Supplement claims tied to a CMS processing delay. That shifts the near-term story from clean growth to growth with health-platform execution risk.

Premium growth remains real, but the mix is less reassuring than the headline. Total premiums rose 7%, led by 16% health-premium growth, yet total underwriting income fell 4% as life margins declined and United American recorded a health underwriting loss. The filing attributes that loss primarily to approximately $16 million of Evry losses and approximately $7 million of excess prior-period Medicare Supplement claims.

The core franchise is still producing growth, but some of the quarter’s profitability was assumption-driven. American Income life premium increased 4%, Liberty National life net sales increased 7%, and Family Heritage health underwriting margin increased 12%. However, the annual reserve-assumption update produced a $120.5 million pretax gain this quarter, versus $134.3 million a year earlier, so the underlying trend should be judged separately from the reported earnings line.

Capital returns partly cushion the result but do not reverse the operating signal. Globe Life repurchased 1.1 million shares for $185 million and increased its full-year buyback expectation to $725 million–$775 million. That supports per-share performance, but it is secondary to the lower earnings outlook and the need to stabilize Evry and Medicare Supplement results.

Bottom line: Globe Life is still growing premiums and returning capital, but Q3 shows that its health expansion is not yet translating cleanly into earnings. The guidance cut makes this a modest earnings miss with a more meaningful execution warning underneath it.

What to watch next

Q3 earnings call, October 22, 2026

Original filing on SEC EDGAR

More Globe Life Inc. news

Globe Life earnings miss as 2026 guidance is cut | GL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.